Professor Mark Febbraio is a Senior Principal Research Fellow of the NHMRC, Australia and the Head of the Cellular and Molecular Metabolism Laboratory within at Monash Institute of Pharmaceutical Sciences, Monash University, Australia. He is also the Founder and CSO of the recently incorporated company DPG-007. His research is focussed on understanding mechanisms associated with exercise, obesity, type 2 diabetes and cancer and his aim is to develop novel drugs to treat lifestyle related diseases. He has authored over 280 peer reviewed papers in leading journals and has over 40,000 career citations. Throughout his career, he has many prestigious awards including the A K McIntyre Prize (1999), the Kellion Award (2017), The Eureka Scientific Prize (2020), The GSK Prize (2020) and The Endocrinology Society International Medal (2021).
« Go Back